You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 369 Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
369 Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies

 

Online download statistics by month:

Online download statistics by month: November 2020 to July 2025

AbstractFullPdf
Nov 2020167018
Dec 20201405
Jan 202122010
Feb 20211807
Mar 202155017
Apr 20212004
May 20211204
Jun 2021004
Jul 2021006
Aug 2021009
Sep 2021007
Oct 202124021
Nov 202132020
Dec 20211401
Jan 20222604
Feb 20222202
Mar 20221003
Apr 20225205
May 20222802
Jun 20222202
Jul 20223801
Aug 20221407
Sep 20221000
Oct 20221201
Nov 20221604
Dec 20222000
Jan 20231206
Feb 20232003
Mar 20231801
Apr 20232203
May 20235408
Jun 20232200
Jul 20233005
Aug 20232204
Sep 20231801
Oct 20232605
Nov 20235203
Dec 20232403
Jan 2024801
Feb 20244000
Mar 20244402
Apr 20241802
May 20244402
Jun 20242403
Jul 20242000
Aug 20241804
Sep 20243203
Oct 20243407
Nov 20241603
Dec 20249606
Jan 20253405
Feb 2025601
Apr 2025004
May 2025006
Jun 2025005
Jul 2025001
Total14020261